Arca
Skip to content
Tools
Tools

Hereditary haemorrhagic telangiectasia

Drug research and approvals for hereditary haemorrhagic telangiectasia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 17 studies of hereditary haemorrhagic telangiectasia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 9 drug trials for it since 2013.

  • Recruiting worldwide: 17
  • Trials authorized in Canada: 9
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 17 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

Newest first; search them all in Canada trials
Jul 31, 2026A randomized, placebo-controlled, double-blind, proof-of-concept study of ATV-1601 in participants with hereditary hemorrhagic telangiectasia (HHT)ATV-1601Atavistik Bio, Inc.Pending
Jul 17, 2026A phase 1/2, first-in-human, multicenter, ascending single-dose and multi-dose study to assess the safety of DIAG723, a novel bispecific ALK-1 and bmprii…DIAG723Diagonal Therapeutics, Inc.Pending
Jun 18, 2026A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of engasertib in subjects with moderate to severe hereditary…Engasertib (VAD044)Vaderis Therapeutics AGPending
Oct 17, 2024A phase 1/2, randomized, double-blind, placebo-controlled 2-part study of the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of single…ALN-6400 / Tranexamic acidAlnylam PharmaceuticalsOngoing
Apr 14, 2022A randomised, placebo controlled, double blind, multicentre proof of concept study to assess the safety and efficacy of two doses of VAD044 in patients with…VAD044Vaderis Therapeutics AGPending
Sep 8, 2021Low-dose sirolimus for nosebleeds in hht: a phase II pilot studySirolimusSt Michaels HospitalPending
Oct 9, 2019Tacrolimus crossover trial for hereditary hemorrhagic telangiectasia (HHT)TacrolimusSt Michaels HospitalPending
Sep 26, 2017Doxycycline crossover trial for hereditary hemorrhagic telangiectasia (HHT)Doxycycline hyclateSt Michaels HospitalOngoing
Sep 11, 2014A phase II study to evaluate the effects of up to 12 weeks of pazopanib dosing on bleeding in subjects with hereditary haemorrhagic telangiectasia.Pazopanib (GW786034)GSKClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.